Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
Journal: Journal of gastroenterology and hepatology
Published: February 06, 2017
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Journal: Annals of hepatology
Published: October 15, 2016
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: September 30, 2016
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Journal: Journal of gastroenterology
Published: April 13, 2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Journal: Journal of gastroenterology and hepatology
Published: December 04, 2015
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Journal: World journal of gastroenterology
Published: August 22, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).
Journal: Antiviral therapy
Published: August 16, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Journal: The New England journal of medicine
Published: July 22, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Journal: JAMA
Published: May 06, 2015
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
Journal: The Journal of infectious diseases
Published: December 05, 2014
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.
Journal: Hepatology (Baltimore, Md.)
Published: July 14, 2014
Last Updated: 09/26/2026